General Motors (GM) announced its partnership with the Henry Ford Health System to ensure wellness services and healthcare management for salaried employees; Democratic and Republican representatives in the House and the Senate have sent separate letters to HHS Secretary Alex Azar on eliminating direct and indirect remuneration fees; despite using infected kidneys in transplant patients, outcomes improved.
In a significant move that establishes the role of the employer as a payer, General Motors (GM) announced its partnership with the Henry Ford Health System to ensure wellness services and healthcare management for salaried employees of the company and their families who reside in Southeast Michigan. This “direct to employer” contract will provide GM employees access to over 3000 primary and specialty care physicians.
Both Democratic and Republican representatives in the House and the Senate have sent separate letters to HHS Secretary Alex Azar asking that the government remove retroactive direct and indirect remuneration (DIR) fees that pharmacies have to pay to Medicare Part D health plans. Inside Health Policy has reported that pharmacists believe that eliminating the DIR fee would significantly lower drug prices, an argument that is fiercely contested by pharmacy benefit managers who operate prescription drug programs for plans.
A small study with 20 patients in need of a kidney transplant found that despite receiving organs infected with hepatitis C, using medications to rid the virus improved patient health. “When there’s such a bad organ shortage, we can’t just do business as usual,” said Peter Reese, MD, MSCE, associate professor of Medicine at the University of Pennsylvania who led the study. “We need to shake off that these organs aren’t valuable and that people will not want them.”
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More